Shire Stock Borsa Italiana

JE00B2QKY057

Analysts' recommendations: Shire

29/08/17

Shire : defends record as UBS cuts price target on staff satisfaction reviews

More recommendations

News in other languages: Shire

08/01/19	EN DIRECT DES MARCHES : Nissan, Dassault Aviation, STMicroelectronics, Sika, Samsung, Tessi...
07/01/19	Les affaires reprennent dans la pharmacie
21/12/18	Walt Disney : Le marché du M&A se prépare à une année 2019 moins faste
18/12/18	Shire : plombé par le déclassement de Takeda
06/12/18	Altran Technologies : Les craintes sur les taux et le commerce font plier les actions en Europe

More news

Shire specializes in developing, producing, and marketing pharmaceutical products for the treatment of nervous system dysfunctions (hyperactivity, epilepsy, Alzheimer's disease, etc.), cancer, gastro-intestinal illnesses, and infectious diseases. Net sales break down by source of income as follows: - sales of products (95.3%); - other (4.7%): primarily franchise royalties. Net sales break down geographically as follows: the United States (63.6%), Ireland (0.4%) and other (36%).

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

21/12/18	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/12/18	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE
21/12/18	British shares falter as Fed, oil play Scrooge	RE
20/12/18	FTSE : GSK pulls FTSE 100 out of three-day rut, focus on Fed	RE
19/12/18	FTSE : Oil slide and growth worries smother FTSE 100 while mid-caps bounce	RE
18/12/18	FTSE : down sharply as ASOS profit alert sparks wider retail selloff	RE
08/12/18	FTSE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs	RE
06/12/18	FTSE : falls as growth angst spreads	RE
06/12/18	Growth and trade nerves grind European shares down to two-week low	RE
05/12/18	Takeda Pharmaceutical : clears key hurdle as investors back $59 billion Shire deal	RE
05/12/18	Takeda Pharmaceutical : investors back $59 billion Shire deal, but wary of debt load	RE
21/11/18	Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition	RE
21/11/18	Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire	RE

13/05/20	Takeda Pharmaceutical : Drugmaker Takeda expects 35% rise in net profit on lower buyout costs	AQ
04/02/20	Takeda Pharmaceutical : lifts FY 2019 earnings projections after Shire buyout	AQ
07/01/19	Shire : Form 8.3 - Takeda Pharmaceutical	PU
07/01/19	Shire : Form 8.3 -	PU
07/01/19	Shire : Form 8.5 (EPT/RI) - Replacement of Shire	PU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SHIRE	-.--%	-.--%	-	-	0
ELI LILLY AND COMPANY	+0.88%	+6.38%	+76.40%	+126.87%	1,119B
JOHNSON & JOHNSON	+1.07%	+3.80%	+50.73%	+64.25%	651B
ABBVIE INC.	+1.20%	+6.21%	+25.81%	+80.15%	468B
ROCHE HOLDING AG	-1.16%	+5.77%	+43.63%	+43.06%	374B
NOVARTIS AG	-0.95%	+4.07%	+24.97%	+41.00%	302B
ASTRAZENECA PLC	-1.14%	+6.81%	+2.27%	+13.65%	259B
AMGEN INC.	+1.88%	+5.81%	+49.57%	+70.71%	238B
NOVO NORDISK A/S	-0.01%	+2.09%	-17.33%	-53.85%	208B
GILEAD SCIENCES, INC.	+1.87%	+5.61%	+27.32%	+89.67%	181B
Average	+0.39%	+5.17%	+31.49%	+52.83%	422.21B
Weighted average by Cap.	+0.55%	+5.40%	+44.26%	+72.42%

Shire Stock Borsa Italiana

Stocks

JE00B2QKY057

Pharmaceuticals

Latest news : Shire

Analysts' recommendations: Shire

Press Releases: Shire

News in other languages: Shire

Other Pharmaceuticals

Company Profile